MRK Merck & Co Inc

$MRK $MRNA $SLS Both Merck and Moderna are mostly green on the day because their cancer vaccine helped patients in a very deadly cancer just like $SLS is about to deliver most consequential Transformative GPS Regal Phase 3 study data in a millennia. ✌️🙏❤️‍🩹

$MRK Very unusual trade 1.5M 130P 100% at the ask, buy. For JAN EXP I'm taking a lotto piggy backing this whale into these 2.70 AVG Under his 2.80 AVG Something smells 'insider' about this, as if the person knowns bad news/event is on the way This is being treated as a whale lotto trade

$MRK $MRNA $BCTX Yes and that’s why a tiny micro micro cap with a platform that has a higher efficacy with minimal side effects, off shelf yet personalized at a fraction of the cost. This will be the true world wide public health miracle for cancer. Fantasy ? We will know in a couple of months when the phase 3 breast cancer trial reports interim results. Moderna’s vaccine a miracle which will be a commercial failure due to the 8 week delay, outrageous cost which insurance companies will not pay. Limited to certain subset.

$MRK Added more here 2.69 avg Something is up with this print into a big catalyst like Sat Pure lotto but could pay 500-1000% if plays out

$MRK $RVMD $SLS 🤯 GPS Next up. 1. E mail from Sellas with just ASH 2026 Event presentation without Actual material because Data is under ASH 2026 Embargo. 2. QP start perfectly aligns with preparation for ASH 2026 Submission. 3. E mail from John F. QP related to Regal Phase 3 only. 4. Dr. Stergiou post Next best Chaper coming. 👇 ✌️🙏❤️‍🩹

$MRK When I saw this order flow whale pre-leak we should have done $MRNA puts instead Fumbled the bag and followed into the MRK PUTS instead of MRNA which moved 700% This whale clearly had inside info on the data days before. I posted this whale flow alert on Oct 20

$MRK so much for the breakout. News drop. Results with $MRNA wasnt as food as expected. Stopped out at a loss

$MRK $MRNA $SLS Exactly! Look at how the market rewards platform validation: • The Phase 2 Proof: Moderna added $20 Billion in value when they first dropped their mid-stage cancer vaccine data. • The Phase 3 Launch: Moderna is absolutely bursting through multi-year highs—adding over $60 Billion in market value since announcing its pivotal Phase 3 results for skin cancer in August. And Moderna achieved that massive enterprise re-rating for a hyper-customized, slow, and expensive platform. We hold the keys to an off-the-shelf, cost-efficient, fridge-ready dual-engine monopoly (GPS + SLS009) right at the final finish line. The REGAL math is locked. The launch sequence is primed. Know what you hold. 💎🙌🔓

$MRK Dumping hard. Owning JAN puts for this to retrace. Whale bought 130 strike and so did I

$MRK BULLFLAG forming on daily right below it's all time highs trendline resistance on daily time frame, $150 break & close on watch for an explosive move out of this flag to $153/$157/$160+ Support: $147/$146

Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027 $MRK $MRNA $XBI https://stocktwits.com/news/equity/markets/merck-endometrial-cancer-drug-cuts-risk-of-death-by-32-fda-decision-due-june-2027/cZU3eYWRBzT

$MRK Merck's sac-TMT lifted endometrial cancer survival to 19.0 from 12.1 months; FDA date set. 🏢 Merck, maker of cancer drug Keytruda, is worth about $350.24B at $141.96 a share as of 11:52 ET on Oct 26, 2026 📈 Merck's Aug 4 Q2 8-K said only that the TroFuse-005 trial met its survival goals, and today's ESMO and Lancet data show sac-TMT cut the risk of death 32% (HR 0.68), lifting median survival to 19.0 months from 12.1 on chemotherapy, a 6.9-month gain ⚠️ The case against is that progression-free survival rose only 3.3 months (7.2 vs 3.9), severe treatment side effects hit 54.4% of sac-TMT patients vs 41.4% on chemotherapy, and these are interim results at 14.0 months median follow-up 📅 Next: FDA target action date (PDUFA) of June 15, 2027 Source: Business Wire release, Oct 26 + SEC 8-K, Aug 4

$MRK Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $2.49 down -3.49% YoY • Reported revenue of $18.09B up 4.68% YoY • Merck & Co. raised and narrowed full-year 2026 sales outlook to $66.8B to $67.3B and non-GAAP EPS outlook to $2.77 to $2.82, including one-time SciBrunch charge.

$MRK — Moderna's melanoma vaccine data leak and its impact on MRK's stock price were the primary focus of recent analyses. Recent analyses examined MRK's stock performance, noting its position relative to its 50-day and 200-day moving averages, and a flattening medium-term uptrend. The reports also covered a data leak concerning a melanoma cancer vaccine co-developed by MRK and Moderna, which led to a slip in MRK's share price.

$MRK Merck reports Q3 Thursday before the open. Zacks consensus is 2.12 dollars EPS on 17.23 billion dollars in revenue, EPS down 17.8% from a year ago, and the estimate has been cut 2.23% in the last 30 days. The segment number is Keytruda. Consensus is 7.45 billion dollars for Q3 after 16.40 billion in the first half, up 4.2%, with the subcutaneous Qlex version contributing 590 million dollars in that half. Merck has beaten the EPS consensus four quarters in a row, even in Q2 when it printed a 13 cent loss against a 26 cent loss expected.

$MRK Price: $145.27 Volume: Average or below Catalyst: Ongoing Keytruda pipeline updates and patent-cliff concerns continue to drive sentiment. Resistance: $149.50 Support: $142.00 Bull case: Reclaiming $149.50 on rising volume opens the door back toward the mid-$150s. Bear case: A breakdown below $142.00 support signals further downside toward the high $130s. What I'm watching: Need volume to confirm any move through either level before trusting the breakout or breakdown. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio:

Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’ $MRK $MRNA $XBI https://stocktwits.com/news/equity/markets/merck-ceo-plays-down-cost-concerns-over-intismeran-we-don-t-see-cost-as-a-limit-to-access/cZxyldnRBxs

$MRK $JNJ Defensive large caps get tradeable dips too. Both pulled back inside uptrends in early Oct: $MRK in at 139.56 and $JNJ at 252.93 on Oct 5, both out two days later, up about 2.5% each. Nothing dramatic. Small, repeatable pops on strong names, sold into the bounce.

$MRK Merck-Moderna melanoma add-on cut recurrence or death risk 42% in Phase 3, not in first 6 months. 🏢 Merck, maker of cancer drug Keytruda, is worth about $366.92B at $148.72 a share, 15:19 ET Oct 22, 2026 📈 After six months of no difference (HR 0.99) during intismeran dosing, risk fell 58% vs Keytruda alone (HR 0.42) in a pre-specified sensitivity analysis ⚠️ Overall survival data are not yet mature, though a favorable trend has been observed and the study continues 📅 Next: Merck Oncology Investor Event at ESMO, Monday, Oct. 26, 2026, 1 p.m. EDT Source: Business Wire release, Oct 22 + SEC 8-K, Aug 4

Shares of Merck, a much larger drugmaker, fell by about 1% on Thursday. The company’s stock has climbed nearly 41% this year. Since the vaccine is personalized, the complicated manufacturing process can take six weeks. But Merck CEO Robert Davis told CNBC last week that the company believes it can shorten that timeline in the future, potentially allowing the shot to reach more patients more quickly. $MRK